PCR-Restriction Fragment Length Polymorphism for Rapid, Low-Cost Identification of Isoniazid-Resistant Mycobacterium tuberculosis
|
|
- Evan Green
- 6 years ago
- Views:
Transcription
1 JOURNAL OF CLINICAL MICROBIOLOGY, June 2007, p Vol. 45, No /07/$ doi: /jcm Copyright 2007, American Society for Microbiology. All Rights Reserved. PCR-Restriction Fragment Length Polymorphism for Rapid, Low-Cost Identification of Isoniazid-Resistant Mycobacterium tuberculosis Maxine Caws, 1,4 * Dau Quang Tho, 1 Phan Minh Duy, 1 Nguyen Thi Ngoc Lan, 2 Dai Viet Hoa, 2 Mili Estee Torok, 1,4 Tran Thi Hong Chau, 3 Nguyen Van Vinh Chau, 3 Nguyen Tran Chinh, 3 and Jeremy Farrar 1,4 Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 190 Ben Ham Tu, District 5, Ho Chi Minh City, Vietnam 1 ; Pham Ngoc Thach Hospital for Tuberculosis and Lung Diseases, Hung Vuong, District 5, Ho Chi Minh City, Vietnam 2 ; The Hospital for Tropical Diseases, 190 Ben Ham Tu, District 5, Ho Chi Minh City, Vietnam 3 ; and Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford, United Kingdom 4 Received 21 September 2006/Returned for modification 3 February 2007/Accepted 29 March 2007 PCR-restriction fragment length poymorphism (PCR-RFLP) is a simple, robust technique for the rapid identification of isoniazid-resistant Mycobacterium tuberculosis. One hundred consecutive isolates from a Vietnamese tuberculosis hospital were tested by MspA1I PCR-RFLP for the detection of isoniazid-resistant katg_315 mutants. The test had a sensitivity of 80% and a specificity of 100% against conventional phenotypic drug susceptibility testing. The positive and negative predictive values were 1 and 0.86, respectively. None of the discrepant isolates had mutant katg_315 codons by sequencing. The test is cheap (less than $1.50 per test), specific, and suitable for the rapid identification of isoniazid resistance in regions with a high prevalence of katg_315 mutants among isoniazid-resistant M. tuberculosis isolates. * Corresponding author. Mailing address: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 190 Ben Ham Tu, Quan 5, Ho Chi Minh City, Vietnam. Phone: (84 8) Fax: (84 8) mcaws@hotmail.com. Published ahead of print on 11 April Tuberculosis (TB) control is threatened by increasing resistance to first-line antituberculous agents. The WHO estimates that in the year 2004, 4.3% of new TB cases globally were multidrug-resistant TB (MDR-TB) (29), defined as resistance to at least isoniazid and rifampin. Treatment regimens for MDR-TB are more complex, less potent, more toxic, and more expensive than first-line regimens, resulting in poorer tolerability and adherence and higher morbidity and mortality rates. Early identification of drug-resistant and particularly MDR strains is routine in developed low-prevalence countries, but the methods are currently unavailable to and too costly for resource-poor nations, where the burden of disease is greatest. Early identification of MDR-TB is crucial in order to permit the timely administration of appropriate drug regimens and could potentially improve the efficacy of MDR treatment schemes, such as directly observed treatment, short course-plus. Isoniazid is a prodrug that is activated through cleavage by catalase peroxidase, the product of the katg gene. The active drug has a complex mode of action, which remains to be fully elucidated but principally targets mycolic acid biosynthesis pathways. Upregulation of the inha gene product, an enoyl- ACP reductase, can overwhelm the impact of isoniazid. Resistance to isoniazid is achieved through mutations in the katg gene, predominantly at codon 315, and in the inha promoter for the majority of isolates. Mutations in other genes, such as ahpc and ndh, have been implicated in isoniazid resistance, but their roles are not yet proven. A role for kasa gene mutation in isoniazid resistance has recently been discredited (7). Many isolates are isoniazid resistant without any mutations in known target genes, and the mechanism of resistance for these isolates remains obscure. Phenotypic sensitivity testing of Mycobacterium tuberculosis is time-consuming, requiring 2 to 4 weeks from primary specimen in settings with rapid liquid culture systems, such as BACTEC MGIT 960, and 6 to 8 weeks in settings with solidmedium culture (14). Several approaches to the rapid identification of isoniazid resistance have been reported in the literature, including realtime PCR (22), single-strand-conformation polymorphism analysis (20), dot blots (25), chips (1, 13), and multiplex-allele-specific PCR (MAS-PCR) (12). The PCR-RFLP approach has several advantages; it is cheap, robust, and simple to both perform and interpret, requiring only basic PCR equipment. MspA1I digestion for the identification of the katg_315 mutation, as discussed here, has been described previously (9, 24, 27). The MspA1I restriction enzyme step also allows the detection of mutations other than katg_s315t at the 315 codon site, increasing the sensitivity of the test over MAS-PCR and still giving a positive identification of both mutant and wild-type genes. It does not detect the very rare katg_s315r (AGC3CGC) mutation (6). Commercial molecular hybridization tests, such as INNO- LiPA RIF TB (Innogenetics, Zwijnaarde, Belgium) and MDRTBI (Hain Lifesciences, Nehren, Germany), while sensitive and specific (10), are too costly for routine use where the burden of disease is greatest. Both of these tests are based on reverse hybridization of a PCR product to membrane-bound probes. The INNO-LiPA RIF TB test detects mutations in the rpob gene and consequently detects only rifampin resistance. However, rifampin resistance can be used as a surrogate marker of MDR-TB in many settings (21, 26). The MDRTBI 1789
2 1790 CAWS ET AL. J. CLIN. MICROBIOL. test has probes targeted to both rpob and katg mutations for the positive identification of MDR strains. The identification of isoniazid resistance in the absence of rifampin resistance is important in settings where primary resistance to both isoniazid and streptomycin is high. Dual resistance to isoniazid and streptomycin, without MDR, has been strongly associated with an increased risk of treatment failure (odds ratio [OR] 4.9; 95% confidence interval [CI], 1.1 to 26) or relapse (OR 3.3; 95% CI, 1.2 to 8.5) and with acquired MDR (OR 6.6; 95% CI, 1.4 to 32) on a standard WHO regimen (2 months of streptomycin, rifampin, isoniazid, and pyrazinamide; 6 months of isoniazid and ethambutol [2SRHZ/6HE]) (17). Around 25% of primary isolates are isoniazid resistant in Ho Chi Minh City, and 15% are isoniazid and streptomycin dual resistant (15). The aim of the current study was to develop a rapid, simple PCR-RFLP screening test for the identification of isoniazid resistance from positive M. tuberculosis cultures. Previous sequencing data on isoniazid-resistant isolates from Vietnam indicated that around 80% of isoniazid-resistant isolates could be detected through katg_315 analysis, with katg_s315t being by far the most prevalent mutation (71%) (3). A restriction enzyme test specific for digestion of the CMGCKG site, found at wild-type katg_315, was therefore developed. The test was expected to detect all the mutations at codon 315 previously identified in Ho Chi Minh City: G944C (S315T), G944A (S315N), G944T (S315I), A943G (S315G), and G944C/C945G (S315T) (3). Rare isolates ( 1% of isoniazid-resistant isolates) that lack the katg gene would not produce an amplicon in the initial PCR (28). To assess specificity, the PCR-RFLP was tested on 47 DNA extracts from M. tuberculosis isolates with previously determined katg sequences (3). The test was 100% specific and was therefore tested prospectively on 100 positive M. tuberculosis cultures collected from patients at the Pham Ngoc Thach Hospital for Tuberculosis and Lung Diseases (PNT TB hospital), Ho Chi Minh City. The costs of the test in routine use were also calculated, based on minimum equipment requirements, costs of reagents available locally, and a batch size of 10 isolates. MATERIALS AND METHODS Sample collection. Initial testing was done on 47 cultures with known katg gene sequences: 20 with S315T mutations, 20 isoniazid-sensitive isolates (wildtype katg), 2 S315N, 2 S315I, 1 S315G, 1 S315T/T308T double mutant, and 1 isolate with a katg whole-gene deletion. The test was then prospectively evaluated on 100 M. tuberculosis cultures from pulmonary TB patients at the PNT TB Hospital during April An aliquot of the first 20 isolates processed for phenotypic drug susceptibility testing each Wednesday was also tested by PCR-RFLP. Drug susceptibility testing (DST) and the PCR-RFLP test were performed blind by two different operators. The sensitivity and specificity of the PCR-RFLP were determined at the end of the study. Any isolate that produced discrepant results with the two tests was sequenced in the katg gene to determine the katg_315 sequence. DNA extraction. A single colony from culture was dispersed in 50 l distilled water, and an equal volume of chloroform was added. The tube was vortexed, heated at 80 C for 20 min, vortexed again, and centrifuged at 12,000 g for 5 min. Five microliters of the upper aqueous layer was taken for PCR. Three control isolates were included with each run: one wild-type positive control, one katg_s315t mutant positive control, and one negative control (water). PCR. PCR of a 519-bp region of the katg gene was carried out with the primers 5 -GGTCGACATTCGCGAGACGTT-3 and 5 -CGGTGGATCAGC TTGTACCAG-3 from Marttila et al. (11). The reaction mixture had a final FIG. 1. PCR-RFLP for the katg_315 mutation conferring isoniazid resistance in M. tuberculosis. Lanes 1, 2, and 5, sensitive clinical isolates; lanes 3 and 4, resistant clinical isolates; lane 6, sensitive control (309-bp band); lane 7, resistant control (377-bp band); lane 8, 100-bp ladder; lane 9, negative control. concentration of 0.3 M each primer, 0.15 mm each deoxynucleoside triphosphate, and 3 mm MgCl 2 with 0.75 U Taq per reaction (Bioline, United Kingdom) (1 Bioline buffer supplied with enzyme). Five microliters of DNA extract was added to 15 l reaction mixture, and the PCR was carried out in a Tetrad PCR machine (Bio-Rad, United Kingdom) with the following program: 10 cycles of 15 s at 95 C, 1 min at 68 C, and 15 s at 72 C, followed by a further 25 cycles of 15 s at 95 C, 15 s at 68 C, and 15 s at 72 C. Restriction enzyme digest. Ten microliters of restriction enzyme mixture was added to each PCR mixture to give a final volume of 30 l containing a final 0.5 U of MspA1I (New England Biolabs), 0.7 New England Biolabs buffer 4 (supplied with enzyme), 100 g/ml bovine serum albumin according to the manufacturer s instructions. The mixture was incubated at 37 C for 2 h in the PCR machine. The products were electrophoresed on a 1.5% agarose gel. A 309-bp band indicated a wild-type katg_315 codon. A 377-bp band indicated a mutant type katg_ 315 codon and therefore izoniazid resistance (Fig. 1). Phenotypic sensitivity testing. Phenotypic sensitivity testing for isoniazid resistance was carried out at 0.2 g/ml by the 1% proportion method at the PNT TB hospital, according to WHO protocols. Sequencing. PCR products were amplified using primers as for the PCR- RFLP test with a program of 30 cycles of 95 C for 15 s, 68 C for 15 s, and 72 C for 15 s. PCR products were purified with QIAgen PCR purification kits (QIAGEN, United Kingdom) and then served as templates for cycle-sequencing reactions. Both strands of each product were sequenced with CEQ Dye Terminator Cycle Sequencing Quick Start kits (Beckman Coulter, Singapore) in half-volume reactions using the same primers. The thermal-cycling program was 96 C for 20 s, appropriate annealing temperature for 20 s, and 60 C for 4 min for 30 cycles, followed by holding at 4 C. The cycle-sequencing products were subjected to ethanol precipitation steps according to the manufacturer s instructions and sequenced on the CEQ8000 system (Beckman Coulter, Singapore). MAS-PCR. MAS-PCR was used to screen for the inha 15C3T mutation in discrepant isolates. The primers were TB92 (3 -CCTCGCTGCCCAGAAAGG GA-5 ; 0.2 m) and TB93 (3 -ATCCCCCGGTTTCCTCCGGT-5 ; 0.05 M) from Telenti et al. (19a), with the internal primer inha Rmut (5 -AGTCACCC CGACAACCTATTA-5 ; 0.25 M). The PCR mixture used 0.2 mm deoxynucleoside triphosphates, 2.5 mm MgCl 2, 0.75 U Bioline Taq (Bioline, United Kingdom), and 1 Taq buffer supplied by the manufacturer. Reaction mixtures were amplified in a Tetrad PCR machine (MJ Research, Hercules, Bio-Rad, United Kingdom), with an initial 2-min denaturation at 94 C, followed
3 VOL. 45, 2007 PCR-RFLP FOR katg_s315t IN M. TUBERCULOSIS 1791 by 30 cycles of 30 s at 94 C, 15 s at 64 C, and 30 s at 72 C, with a final 2-min elongation at 72 C. The presence of two bands at 174 bp and 248 bp indicated a mutant allele (inha 15C3T). Wild-type isolates generated only a single band at 248 bp. Costs. Cost calculations were based on a batch size of 10 isolates, with all reagents purchased through local distributors and an exchange rate of 15,900 VND to the U.S. dollar. Equipment cost estimates were based upon locally available catalogue prices. The cheapest appropriate models were selected for calculations rather than the relatively expensive multiplate gradient models used in our laboratory, as only a basic thermocycler is required to perform the test. Costs were averaged and rounded up to the nearest $50. Final costs were estimated in U.S. dollars. RESULTS Retrospective culture analysis. The test was 100% specific for the detection of the katg_315 mutant codon on 47 retrospective cultures with known katg_315 sequences. The 20 isoniazid-sensitive isolates produced a wild-type 310-bp band, and 27 resistant isolates with miscellaneous mutations at katg_315 generated a 378-bp band (Fig. 1). The isolate with katg deleted failed to generate an amplicon, as predicted, and the result was therefore uninterpretable. This DNA extract generated a product with other PCR-based tests, including spoligotyping and rpob and inha sequencing (data not shown). Prospective culture analysis. Of 100 M. tuberculosis cultures tested at the PNT TB Hospital by PCR-RFLP, 35 were resistant, 64 were wild type, and 1 isolate generated both wild-type and resistant bands and was therefore deemed to be a mixed culture. By phenotypic DST, 43 isolates were resistant to isoniazid (one of which was identified as Mycobacterium fortuitum), 55 were sensitive, and 2 failed to return a result due to failed growth or contamination (both of which were sensitive by PCR-RFLP). Excluding the two isolates that failed to return a result by DST and the M. fortuitum isolate, the sensitivity of the PCR-RFLP test was 80% and the specificity was 100%. The positive predictive value and negative predictive value were 1 and 0.86, respectively. Nine discrepant isolates were sequenced in the katg gene, including seven isolates that returned a sensitive PCR-RFLP/ resistant DST result, one isolate (RE188) that returned a mixed resistant/sensitive PCR-RFLP result with a resistant DST result, and 1 isolate that returned a resistant PCR-RFLP result but was identified as M. fortuitum by DST (RE180). These isolates were also screened for the inha 15C3T mutation by MAS PCR. A summary of the discrepant isolates is presented in Table 1. The sequencing results confirmed that isolate RE180 contained M. tuberculosis DNA and carried a katg_s315t mutation. Isolate RE188 produced a heteropeak for the relevant mutation at codon 315 (G944C/wild type), confirming that it contained a mixed population of resistant and sensitive organisms. The six remaining isolates carried a wild-type katg_315 codon, with one isolate (RE239) carrying a novel mutation in katg, C1132A (L378M), confirming that in all these isolates resistance was attributable to mutations at sites other than katg_315. The median time to positive culture was 32 days (range, 19 to 55 days; data were available for only 58 cultures). Phenotypic DST testing required a further 41 days to return a result, with PCR-RFLP returning a result within 1 day. TABLE 1. katg gene sequences of isolates showing nine discrepant results with PCR-RFLP and phenotypic DST Isolate no. PCR-RFLP DST Result Costs. The capital equipment required for the test consists of a basic PCR machine (approximately $3,000), a gel tank ($550), a power pack ($1,600), a transilluminator ($1,000), a camera ($400), and four pipettes ($1,000). The total capital costs are approximately $7,550. However, this equipment can also be used for other tests once it is purchased and is already available in many reference level laboratories. If 10 isolates are processed per batch, with three controls (a positive mutant control, a positive wild-type control, and a negative control), the cost of each test is $1.50 per isolate. Labor costs were not included in this calculation. DISCUSSION katg sequencing inha 15C3T MAS PCR RE180 Resistant M. fortuitum S315T WT RE188 Sensitive/resitant Resistant S315T/WT a WT RE194 Sensitive Resistant WT 15C3T RE207 Sensitive Resistant WT WT RE220 Sensitive Resistant WT WT RE227 Sensitive Resistant WT WT RE239 Sensitive Resistant L378M 15C3T RE250 Sensitive Resistant WT 15C3T RE259 Sensitive Resistant WT WT a Isolate RE188 showed a heteropeak (G/C) at katg_315, nucleotide 944. WT, wild type. The MspA1I PCR-RFLP rapid test described above showed 100% specificity and 80% sensitivity in the routine identification of isoniazid-resistant M. tuberculosis. It is affordable and simple to perform. It was also possible to obtain screening results by PCR-RFLP for three isolates that failed to return results by phenotypic DST due to failed regrowth or contamination. Isolate RE180 was originally identified as M. fortuitum at the PNT laboratory, and the presence of M. tuberculosis DNA, shown by katg sequencing, in the original culture extract of isolate RE180 suggests that a laboratory contamination event at the phenotypic DST subculture stage led to the growth of M. fortuitum. However, it is impossible to rule out contamination of an M. fortuitum sample with M. tuberculosis DNA during PCR-RFLP sample processing for DNA extraction. Unfortunately, clinical data were not available from the patient to determine if M. tuberculosis was isolated from later samples. The early detection of isoniazid resistance is an important step in reducing the use of drug resistance-amplifying regimens, particularly with the increasing availability of secondline drugs through schemes such as DOTS-PLUS. Mutations in katg_315 are associated with higher MICs for isoniazid than mutations in the inha promoter and therefore are probably of greater clinical significance (18, 23, 24). Variations in the outcomes of standard treatment regimens with a primary isoniazidresistant organism are multifactorial, but the MIC for the isolate may be a contributing factor. Vietnam has an estimated primary isoniazid resistance rate of 25% in Ho Chi Minh City (15). Despite having a wellfunctioning National Tuberculosis Program (NTP) administering DOTS according to WHO guidelines (8), drug resistance
4 1792 CAWS ET AL. J. CLIN. MICROBIOL. continues to rise. It has been speculated that this is due to high rates of primary isoniazid resistance in conjunction with the use of isonizid/ethambutol continuation phase regimens (16). Of greatest concern is the evidence that this may be fueling the development of MDR-TB, which has seen an increase from 2.3% in 1997 to an estimated 3.8% in 2005 (15). There is therefore an urgent need for a cheap, rapid, simple test to diagnose isoniazid resistance prior to the continuation phase, when currently around 25% of patients in Vietnam effectively receive monotherapy due to polyresistance. Primary isoniazid resistance has been associated with the development of MDR-TB after treatment (17). The katg_315 mutation is associated with the development and transmission of MDR-TB, whereas other isoniazid resistance-conferring mutations, such as inha 15C3T, are not (7, 23, 24). The test described here is economical ($1.50 per isolate) and simple to perform. In routine laboratories, the cost per isolate is likely to be lower, as we used a batch size of 10 isolates for calculations whereas larger batch sizes of 20 to 30 could easily be processed with careful precautions against contamination, including the use of clean and dirty containment areas and dutps with enzyme digestion and increasing the number of negative controls in larger batches. Currently, in the Vietnamese NTP, TB patients are tested for drug resistance only after the microbiological failure of first-line therapy. This is primarily because of cost and workload considerations. Although the PCR-RFLP test is not 100% sensitive for the detection of isoniazid resistance, it is 100% specific and can therefore be used as a rapid screening test to identify the majority of patients with isoniazid-resistant organisms. At $1.50 per test, it is also affordable. The test can be completed in 1 day and requires around 2 to 3 h of hands-on time if already-prepared PCR master mixtures are used. We are currently evaluating the test for routine use directly with smear-positive sputum. Strategies for the rapid identification of drug resistance should be region specific. A test screening for katg_315 mutations is likely to be of the most use in regions with a high prevalence of this mutation, such as China, Russia, the former Soviet states, Vietnam, and Peru (3, 5). In Europe, a higher prevalence of inha gene mutations indicates that a multiplex PCR or hybridization approach is warranted (2, 4, 19). The reasons for variations in mutation prevalence are unclear and may be related to TB control program differences or to variations in the predominant M. tuberculosis strains within a region. Assessment of strategies for the rapid identification of drug resistance should be made in the context of knowledge of the predominant resistance-conferring mutations in a region. In Vietnam, several factors should be considered: high underlying isoniazid resistance, the rarity of rifampin resistance without isoniazid resistance, and diverse rifampin resistance mutation patterns complicating the identification of rifampin resistance (3). These factors suggest an approach based upon rapid isoniazid resistance screening, with subsequent rifampin resistance testing in isoniazid-resistant isolates. The implementation of rapid resistance-screening tests in high-incidence areas must be carefully considered. In Vietnam, as in many developing countries, patients whose primary therapy fails are treated with a standard first-line retreatment regimen. Even after identification of drug resistance by DST, TB therapy is rarely modified, even though treatment success rates with standard first-line drug retreatment regimens are known to be low. The advent of DOTS-PLUS schemes supported by the Green Light Committee for the economical procurement of drugs makes the implementation of rapid drug resistance screening and the use of second-line treatment regimes feasible within a well-established NTP such as is found in Vietnam. The use of the PCR-RFLP test to rapidly identify isoniazid resistance and to guide timely modification of therapy could potentially reduce both the generation and transmission of MDR-TB. ACKNOWLEDGMENTS This work was funded by Wellcome Trust Grant /Z/05/Z. We thank the staff of Pham Ngoc Thach Microbiology laboratory for assistance with this study. REFERENCES 1. Aragon, L. M., F. Navarro, V. Heiser, M. Garrigo, M. Espanol, and P. Coll Rapid detection of specific gene mutations associated with isoniazid or rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluorescent low-density DNA microarrays. J. Antimicrob. Chemother. 57: Baker, L. V., T. J. Brown, O. Maxwell, A. L. Gibson, Z. Fang, M. D. Yates, and F. A. Drobniewski Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpc 46A polymorphism. Antimicrob. Agents Chemother. 49: Caws, M., P. M. Duy, D. Q. Tho, N. T. Lan, D. V. Hoa, and J. Farrar Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J. Clin. Microbiol. 44: Coll, P., L. M. Aragon, F. Alcaide, M. Espasa, M. Garrigo, J. Gonzalez, J. M. Manterola, P. Orus, and M. Salvado Molecular analysis of isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates recovered from Barcelona. Microb. Drug Resist. 11: Escalante, P., S. Ramaswamy, H. Sanabria, H. Soini, X. Pan, O. Valiente- Castillo, and J. M. Musser Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber Lung Dis. 79: Haas, W. H., K. Schilke, J. Brand, B. Amthor, K. Weyer, P. B. Fourie, G. Bretzel, V. Sticht-Groh, and H. J. Bremer Molecular analysis of katg gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob. Agents Chemother. 41: Hazbon, M. H., M. Brimacombe, M. Bobadilla del Valle, M. Cavatore, M. I. Guerrero, M. Varma-Basil, H. Billman-Jacobe, C. Lavender, J. Fyfe, L. Garcia-Garcia, C. I. Leon, M. Bose, F. Chaves, M. Murray, K. D. Eisenach, J. Sifuentes-Osornio, M. D. Cave, A. Ponce de Leon, and D. Alland Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50: Huong, N. T., B. D. Duong, N. V. Co, H. T. Quy, L. B. Tung, M. Bosman, A. Gebhardt, J. P. Velema, J. F. Broekmans, and M. W. Borgdorff Establishment and development of the National Tuberculosis Control Programme in Vietnam. Int. J. Tuberc. Lung Dis. 9: Leung, E. T., K. M. Kam, A. Chiu, P. L. Ho, W. H. Seto, K. Y. Yuen, and W. C. Yam Detection of katg Ser315Thr substitution in respiratory specimens from patients with isoniazid-resistant Mycobacterium tuberculosis using PCR-RFLP. J. Med. Microbiol. 52: Makinen, J., H. J. Marttila, M. Marjamaki, M. K. Viljanen, and H. Soini Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 44: Marttila, H. J., H. Soini, P. Huovinen, and M. K. Viljanen katg mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients. Antimicrob. Agents Chemother. 40: Mokrousov, I., T. Otten, M. Filipenko, A. Vyazovaya, E. Chrapov, E. Limeschenko, L. Steklova, B. Vyshnevskiy, and O. Narvskaya Detection of isoniazid-resistant Mycobacterium tuberculosis strains by a multiplex allelespecific PCR assay targeting katg codon 315 variation. J. Clin. Microbiol. 40: Park, H., E. J. Song, E. S. Song, E. Y. Lee, C. M. Kim, S. H. Jeong, J. H. Shin, J. Jeong, S. Kim, Y. K. Park, G. H. Bai, and C. L. Chang Comparison of a conventional antimicrobial susceptibility assay to an oligonucleotide chip system for detection of drug resistance in Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 44:
5 VOL. 45, 2007 PCR-RFLP FOR katg_s315t IN M. TUBERCULOSIS Piersimoni, C., A. Olivieri, L. Benacchio, and C. Scarparo Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J. Clin. Microbiol. 44: Quy, H. T., T. N. Buu, F. G. Cobelens, N. T. Lan, C. S. Lambregts, and M. W. Borgdorff Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis. 10: Quy, H. T., F. G. Cobelens, N. T. Lan, T. N. Buu, C. S. Lambregts, and M. W. Borgdorff Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis. 10: Quy, H. T., N. T. Lan, M. W. Borgdorff, J. Grosset, P. D. Linh, L. B. Tung, D. van Soolingen, M. Raviglione, N. V. Co, and J. Broekmans Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int. J. Tuberc. Lung Dis. 7: Ramaswamy, S. V., R. Reich, S. J. Dou, L. Jasperse, X. Pan, A. Wanger, T. Quitugua, and E. A. Graviss Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47: Rindi, L., L. Bianchi, E. Tortoli, N. Lari, D. Bonanni, and C. Garzelli Mutations responsible for Mycobacterium tuberculosis isoniazid resistance in Italy. Int. J. Tuberc. Lung Dis. 9: a.Telenti, A., N. Honore, C. Bernasconi, J. March, A. Ortega, B. Heym, H. E. Takiff, and S. T. Cole. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a bind study at reference laboratory level. J. Clin. Microbiol. 35: Temesgen, Z., K. Satoh, J. R. Uhl, B. C. Kline, and F. R. Cockerill III Use of polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) analysis to detect a point mutation in the catalase-peroxidase gene (katg) of Mycobacterium tuberculosis. Mol. Cell Probes 11: Traore, H., K. Fissette, I. Bastian, M. Devleeschouwer, and F. Portaels Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int. J. Tuberc. Lung Dis. 4: van Doorn, H. R., E. C. Claas, K. E. Templeton, A. G. van der Zanden, A. te Koppele Vije, M. D. de Jong, J. Dankert, and E. J. Kuijper Detection of a point mutation associated with high-level isoniazid resistance in Mycobacterium tuberculosis by using real-time PCR technology with 3 -minor groove binder-dna probes. J. Clin. Microbiol. 41: van Doorn, H. R., P. E. de Haas, K. Kremer, C. M. Vandenbroucke-Grauls, M. W. Borgdorff, and D. van Soolingen Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at aminoacid position 315 of katg: a decade of experience in The Netherlands. Clin. Microbiol. Infect. 12: van Soolingen, D., P. E. de Haas, H. R. van Doorn, E. Kuijper, H. Rinder, and M. W. Borgdorff Mutations at amino acid position 315 of the katg gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J. Infect. Dis. 182: Victor, T. C., A. M. Jordaan, A. van Rie, G. D. van der Spuy, M. Richardson, P. D. van Helden, and R. Warren Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot hybridization strategy. Tuber Lung Dis. 79: Watterson, S. A., S. M. Wilson, M. D. Yates, and F. A. Drobniewski Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 36: Wojtyczka, R. D., S. Dworniczak, J. Pacha, D. Idzik, M. Kepa, Z. Wydmuch, S. Glab, M. Bajorek, K. Oklek, and J. Kozielski PCR-RFLP analysis of a point mutation in codons 315 and 463 of the katg gene of Mycobacterium tuberculosis isolated from patients in Silesia, Poland. Pol. J. Microbiol. 53: Zhang, Y., B. Heym, B. Allen, D. Young, and S. Cole The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358: Zignol, M., M. S. Hosseini, A. Wright, C. L. Weezenbeek, P. Nunn, C. J. Watt, B. G. Williams, and C. Dye Global incidence of multidrugresistant tuberculosis. J. Infect. Dis. 194: Downloaded from on April 30, 2018 by guest
PCR-RFLP for rapid, low-cost identification of isoniazid-resistant Mycobacterium ACCEPTED
JCM Accepts, published online ahead of print on April 00 J. Clin. Microbiol. doi:./jcm.010-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationMutations Prevalent among Rifampin- and Isoniazid-Resistant Mycobacterium tuberculosis Isolates from a Hospital in Vietnam
JOURNAL OF CLINICAL MICROBIOLOGY, July 2006, p. 2333 2337 Vol. 44, No. 7 0095-1137/06/$08.00 0 doi:10.1128/jcm.00330-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Mutations
More informationPrimary Multi Drug Resistance in New Pulmonary Tuberculosis Patients in Western Uttar Pradesh, India
ISSN: 2319-7706 Volume 4 Number 8 (2015) pp. 656-663 http://www.ijcmas.com Original Research Article Primary Multi Drug Resistance in New Pulmonary Tuberculosis Patients in Western Uttar Pradesh, India
More informationEvaluation of the MTBDRsl Test for Detection of Second-Line-Drug Resistance in Mycobacterium tuberculosis
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2010, p. 2934 2939 Vol. 48, No. 8 0095-1137/10/$12.00 doi:10.1128/jcm.00201-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Evaluation
More informationGenetic Polymorphism at Codon 463 in the katg Gene in Isoniazid-Sensitive and -Resistant Isolates of Mycobacterium tuberculosis from the Middle East
Original Paper Med Principles Pract 2001;10:129 134 Received: January 31, 2001 Revised: May 14, 2001 Genetic Polymorphism at Codon 463 in the katg Gene in Isoniazid-Sensitive and -Resistant Isolates of
More informationAuthor s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis
Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis Authors: Phan Thai (phanvuongkhacthai@yahoo.com) Dang Ha
More informationMolecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.
Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01495.x Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katg: a decade of experience
More informationResearch Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal
Hindawi International Scholarly Research Notices Volume 2017, Article ID 1635780, 5 pages https://doi.org/10.1155/2017/1635780 Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant
More informationRapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa
Journal of Antimicrobial Chemotherapy Advance Access published October 21, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn433 Rapid genotypic assays to identify drug-resistant Mycobacterium
More informationMultiplex PCR for Rapid Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Isolated from Bandung, Indonesia
MICOBIOLOGY INDONESIA, December 007, p 4 Volume, Number 3 ISSN 973477 Multiplex PC for apid Detection of ifampin and Isoniazid esistance in Mycobacterium tuberculosis Isolated from Bandung, Indonesia HEA
More informationDRUG RESISTANCE IN TUBERCULOSIS
DRUG RESISTANCE IN TUBERCULOSIS INTRODUCTION Up to 50 million people may be infected with drug-resistant resistant TB.* Hot zones of MDR-TB such as Russia, Latvia, Estonia, Argentina and the Dominican
More informationA simple, rapid and economic method for detecting multidrug-resistant tuberculosis
braz j infect dis. 2013;17(6):667 671 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original article A simple, rapid and economic method for detecting multidrug-resistant tuberculosis
More informationIgor Mokrousov, 1 * Olga Narvskaya, 1 Tatiana Otten, 2 Elena Limeschenko, 1 Lidia Steklova, 3 and Boris Vyshnevskiy 2
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2002, p. 1417 1424 Vol. 46, No. 5 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.5.1417 1424.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationMultidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates
Eur J Clin Microbiol Infect Dis (2008) 27:1079 1086 DOI 10.1007/s10096-008-0548-9 ARTICLE Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid
More informationThe Efficacy of Genotype MTBDRplus Assay in Rapid Detection of Rifampicin and Isoniazid Resistance in Mycobacterium tuberculosis Complex Isolates
The Efficacy of Genotype MTBDRplus Assay in Rapid Detection of Rifampicin and Isoniazid Resistance in Mycobacterium tuberculosis Complex Isolates Singh Shruti S 1, Desai Pratibha B. 2 1,2 Department of
More informationReceived 24 August 2007/Returned for modification 17 October 2007/Accepted 27 November 2007
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2008, p. 725 729 Vol. 52, No. 2 0066-4804/08/$08.00 0 doi:10.1128/aac.01124-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Prevalence
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationIsoniazid MIC and KatG Gene Mutations among Mycobacterium tuberculosis Isolates in Northwest of Iran
Iranian Journal of Basic Medical Sciences Vol. 14, No. 6, Nov-Dec 2011, 540-545 Received: Mar 5, 2011; Accepted: Jun 20, 2011 Original article Isoniazid MIC and KatG Gene Mutations among Mycobacterium
More informationMolecular Methods in the Diagnosis of Drug Resistant Tuberculosis. Dr Sahajal Dhooria
Molecular Methods in the Diagnosis of Drug Resistant Tuberculosis Dr Sahajal Dhooria What is drug resistant TB? Definitions MDR TB defined as resistance to isoniazid and rifampicin, with or without resistance
More informationDepartment of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
Indian J Med Res 135, May 2012, pp 756-762 Variations in the occurrence of specific rpob mutations in rifampicinresistant Mycobacterium tuberculosis isolates from patients of different ethnic groups in
More informationGenotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico
Journal of Medical Microbiology (2004), 53, 107 113 DOI 10.1099/jmm.0.05343-0 Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico Srinivas V. Ramaswamy,
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationDrug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER
Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility
More informationRapid detection of mutations in rpob gene of rifampicin resistant Mycobacterium tuberculosis strains by line probe assay
Indian J Med Res 117, February 2003, pp 76-80 Rapid detection of mutations in rpob gene of rifampicin resistant Mycobacterium tuberculosis strains by line probe assay Meera Sharma, Sunil Sethi, Baijayantimala
More informationValidation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam
RESEARCH ARTICLE Open Access Research article Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam Mai NT Huyen 1, Edine W Tiemersma* 2,3, Nguyen
More informationTuberculosis Elimination, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
ORIGINAL ARTICLE 10.1111/j.1469-0691.2007.01711.x Association of specific mutations in katg, rpob, rpsl and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia
More informationMultidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area
Rapid communications Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area C Ködmön (csaba.kodmon@ecdc.europa.eu)
More informationMolecular Analysis of Isoniazid and Rifampin Resistance in Mycobacterium tuberculosis Isolates Recovered from Barcelona ABSTRACT
MICROBIAL DRUG RESISTANCE Volume 11, Number 2, 2005 Mary Ann Liebert, Inc. Molecular Analysis of Isoniazid and Rifampin Resistance in Mycobacterium tuberculosis Isolates Recovered from Barcelona PERE COLL,
More informationMulti-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis
JCM Accepts, published online ahead of print on 30 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00678-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Multi-clonal origin
More informationAnalysis of mutational pattern in multidrug resistant tuberculosis (MDR TB) in a geographically isolated northeastern region of India
IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-issn: 2278-3008, p-issn:2319-7676. Volume 9, Issue 1 Ver. III (Jan. 2014), PP 04-10 Analysis of mutational pattern in multidrug resistant
More informationTransmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos
Transmissibility, virulence and fitness of resistant strains of M. tuberculosis CHIANG Chen-Yuan MD, MPH, DrPhilos Transmissibility, Virulence and Fitness of resistant strains of M. tuberculosis For infectious
More informationMolecular diagnosis of MDR-TB using GenoType MTBDRplus 96 assay in Ibadan, Nigeria
Niger. J. Physiol. Sci. 28(December 2013) 187 191 www.njps.com.ng Molecular diagnosis of MDR-TB using GenoType MTBDRplus 96 assay in Ibadan, Nigeria * 1 Kehinde A.O. and 2 Adebiyi, E.O. Department of Medical
More informationRapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array
ORIGINAL ARTICLE BACTERIOLOGY Rapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array W.-L. Huang 1, Z.-J. Hsu 1, T. C. Chang 2 and R.
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationA. Nusrath Unissa, N. Selvakumar, Sujatha Narayanan, C. Suganthi, and L. E. Hanna
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 257983, 5 pages http://dx.doi.org/10.1155/2015/257983 Research Article Investigation of Ser315 Substitutions within
More informationkatg Mutation of Isoniazid-Resistant Isolated from Tuberculosis Patients
ORIGINAL RESEARCH ARTICLE Tanaffos (2006) 5(), 3-36 2006 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran katg Mutation of Isoniazid-Resistant Isolated from Tuberculosis Patients
More informationMulti-drug Resistant Tuberculosis in Rajshahi District
TAJ December 2005; Volume 18 Number 2 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Original Article Multi-drug Resistant Tuberculosis in Rajshahi District M Wasim Hussain, 1 M Azizul
More informationMolecular Characterization of Isoniazid-Resistant Mycobacterium tuberculosis Isolates Collected in Australia
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2005, p. 4068 4074 Vol. 49, No. 10 0066-4804/05/$08.00 0 doi:10.1128/aac.49.10.4068 4074.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationLaboratory Diagnosis for MDR TB
Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe
More informationMycobacterium tuberculosis and Molecular Epidemiology: An Overview
Journal of Microbiology Research 2014, 4(6A): 25-31 DOI: 10.5923/s.microbiology.201401.04 Mycobacterium tuberculosis and Molecular Epidemiology: An Overview Asho Ali Department of Biology, King Abdul Aziz
More informationBMC Infectious Diseases
BMC Infectious Diseases This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. Rapid screening of
More informationAccepted 13 September, 2011
African Journal of Microbiology Research Vol. 5(26), pp. 4519-4523, 16 November, 2011 Available online at http://www.academicjournals.org/ajmr ISSN 1996-0808 2011 Academic Journals DOI: 10.5897/AJMR11.358
More informationOnline Annexes (2-4)
Online Annexes (2-4) to WHO Policy update: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin THE END TB STRATEGY Online Annexes (2-4) to WHO Policy update:
More informationCDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service
CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service Beverly Metchock, DrPH, D(ABMM) Team Lead, Reference Laboratory
More informationDetection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 1543-1549 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.185
More informationTB Updates for the Physician Rochester, Minnesota June 19, 2009
TB Updates for the Physician Rochester, Minnesota June 19, 2009 Mycobacterial Laboratory Science Update Nancy L. Wengenack, Ph.D. Associate Professor of Laboratory Medicine and Pathology Division of Clinical
More informationHarmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis
Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis Grace Lin, MS. Research Scientist grace.lin@cdph.ca.gov APHL 8 th TB Lab Conference San Diego 8-19-13 Harmonizing? There
More informationA household survey on screening practices of household contacts of smear positive tuberculosis patients in Vietnam
Thanh et al. BMC Public Health 2014, 14:713 RESEARCH ARTICLE Open Access A household survey on screening practices of household contacts of smear positive tuberculosis patients in Vietnam Thuy Hoang Thi
More informationMultidrug resistance (MDR) epitomises. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan
Eur Respir J 2009; 33: 368 374 DOI: 10.1183/09031936.00089808 CopyrightßERS Journals Ltd 2009 Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan
More informationInconsistent Results with the Xpert-MTB/Rif Assay in Detection of Mycobacterium
JCM Accepts, published online ahead of print on 12 July 2013 J. Clin. Microbiol. doi:10.1128/jcm.01377-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Inconsistent Results
More informationReceived 26 June 2005/Returned for modification 17 August 2005/Accepted 21 October 2005
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2006, p. 201 205 Vol. 44, No. 1 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.1.201 205.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Use
More informationEvaluation of the MODS Culture Technique for the Diagnosis of Tuberculous Meningitis
Evaluation of the Culture Technique for the Diagnosis of Tuberculous Meningitis Maxine Caws 1,4 *, Dang Thi Minh Ha 1,2, Estee Torok 1,4, James Campbell 1,4, Do Dang Anh Thu 1, Tran Thi Hong Chau 3, Nguyen
More informationXin-Feng Wang 1, Jun-Li Wang 2, Mao-Shui Wang 1. Introduction
Original Article Page 1 of 6 Evaluation of GenoType MTBDRplus assay for rapid detection of isoniazid- and rifampicin-resistance in Mycobacterium tuberculosis isolates from diabetes mellitus patients Xin-Feng
More informationRapid Detection of Rifampin Resistance in Mycobacterium tuberculosis Isolates from India and Mexico by a Molecular Beacon Assay
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2004, p. 5512 5516 Vol. 42, No. 12 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.12.5512 5516.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationAspirin antagonism in isonizaid treatment of tuberculosis in mice ACCEPTED. Department of Molecular Microbiology & Immunology, Bloomberg School of
AAC Accepts, published online ahead of print on 4 December 2006 Antimicrob. Agents Chemother. doi:10.1128/aac.01145-06 Copyright 2006, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationPrevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012
Yin et al. BMC Microbiology (2016) 16:85 DOI 10.1186/s12866-016-0699-2 RESEARCH ARTICLE Open Access Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China:
More informationJillian Dormandy, BS; Akos Somoskovi, MD, PhD; Barry N. Kreiswirth, PhD; Jeffrey R. Driscoll, PhD; David Ashkin, MD; and Max Salfinger, MD
Original Research LUNG INFECTION Discrepant Results Between Pyrazinamide Susceptibility Testing by the Reference BACTEC 460TB Method and pnca DNA Sequencing in Patients Infected With Multidrug-Resistant
More informationEvaluation of the Microscopic-Observation. Drug-Susceptibility Assay Drugs Concentration for Detection Of Multidrug-Resistant Tuberculosis
Evaluation of the Microscopic-Observation Drug-Susceptibility Assay Drugs Concentration for Detection Of Multidrug-Resistant Tuberculosis ABSTRACT New diagnostic tools are urgently needed to interrupt
More informationKit Components Product # EP42720 (24 preps) MDx 2X PCR Master Mix 350 µl Cryptococcus neoformans Primer Mix 70 µl Cryptococcus neoformans Positive
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Cryptococcus neoformans End-Point PCR Kit Product# EP42720 Product
More informationDNA sequencing for the confirmation of rifampin resistance detected by Cepheid Xpert
JCM Accepted Manuscript Posted Online 4 March 2015 J. Clin. Microbiol. doi:10.1128/jcm.03433-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 DNA sequencing for the confirmation
More informationMIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex
MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex Marie Claire Rowlinson, PhD D(ABMM) Florida Bureau of Public Health Laboratories
More informationDST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?
DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps? Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and
More informationCorrelation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance
ORIGINAL ARTICLE https://doi.org/10.4046/trd.2018.0027 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis, Respir Dis 2019;82:143-150 Correlation between GenoType MTBDRplus Assay and Phenotypic
More informationMultidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment
Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment L. P. Ormerod Chest Clinic, Blackburn Royal Infirmary, Blackburn, Lancs BB2 3LR, and Postgraduate School of Medicine and
More informationDetection of Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis Isolates from China
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2005, p. 5477 5482 Vol. 43, No. 11 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.11.5477 5482.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationThe New England Journal of Medicine EXOGENOUS REINFECTION AS A CAUSE OF RECURRENT TUBERCULOSIS AFTER CURATIVE TREATMENT
EXOGENOUS REINFECTION AS A CAUSE OF RECURRENT TUBERCULOSIS AFTER CURATIVE TREATMENT ANNELIES VAN RIE, M.D., ROBIN WARREN, PH.D., MADELEINE RICHARDSON, M.SC., THOMAS C. VICTOR, PH.D., ROBERT P. GIE, M.D.,
More informationReceived 4 June 2013; Final revision 1 August 2013; Accepted 30 August 2013; first published online 27 September 2013
Epidemiol. Infect. (2014), 142, 1328 1333. Cambridge University Press 2013 doi:10.1017/s0950268813002409 SHORT REPORT Characterization of multi-drug resistant Mycobacterium tuberculosis from immigrants
More informationProduct # Kit Components
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Pneumocystis jirovecii PCR Kit Product # 42820 Product Insert Background Information
More informationWhite Paper Application
White Paper Application Project Title: Whole genome sequencing of clinical strains of Mycobacterium tuberculosis Authors: David Alland, Jerrold Ellner, Susan Dorman, Moses Joloba, Clifton Barry Primary
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationRole of Paired Box9 (PAX9) (rs ) and Muscle Segment Homeobox1 (MSX1) (581C>T) Gene Polymorphisms in Tooth Agenesis
EC Dental Science Special Issue - 2017 Role of Paired Box9 (PAX9) (rs2073245) and Muscle Segment Homeobox1 (MSX1) (581C>T) Gene Polymorphisms in Tooth Agenesis Research Article Dr. Sonam Sethi 1, Dr. Anmol
More informationDrug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye
Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case
More informationChallenges in Capacity in SA for diagnosing DR-TB
National Tuberculosis Reference Laboratory Challenges in Capacity in SA for diagnosing DR-TB March 2010 Gerrit Coetzee Rapid response to XDR-TB WHO Global Task Force on XDR-TB, October 2006 Accelerate
More informationNorgen s HIV Proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad T1000 Cycler
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com HIV Proviral DNA PCR Kit Product# 33840 Product Insert Intended
More informationRapid detection of multidrug-resistant tuberculosis
Eur Respir J 1997; 10: 1120 1124 DOI: 10.1183/09031936.97.10051120 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Rapid detection of multidrug-resistant
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationPatterns of rpoc Mutations in Drug-Resistant Mycobacterium tuberculosis Isolated from Patients in South Korea
ORIGINAL ARTICLE https://doi.org/10.4046/trd.2017.0042 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2018;81:222-227 Patterns of rpoc Mutations in -Resistant Mycobacterium tuberculosis Isolated
More informationkatg Gene as a Surrogate Molecular Marker Leading to Cause Drug Resistance in Mycobacterium tuberculosis Isolates
American Journal of Infectious Diseases and Microbiology, 2013, Vol. 1, No. 5, 86-91 Available online at http://pubs.sciepub.com/ajidm/1/5/2 Science and Education Publishing DOI:10.12691/ajidm-1-5-2 katg
More informationReceived 8 June 2006/Returned for modification 12 July 2006/Accepted 16 August 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2006, p. 3934 3939 Vol. 44, No. 11 0095-1137/06/$08.00 0 doi:10.1128/jcm.01181-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Beijing
More informationMYCOBACTERIUM TUBERCULOSIS GENETIC DIVERSITY AND DRUG RESISTANCE CONFERRING MUTATIONS IN THE DEMOCRATIC REPUBLIC OF THE CONGO
December 2011 Ea s t Af r i c a n Me d i c a l Jo u r n a l 409 East African Medical Journal Vol. 88 No. 12 December 2011 MYCOBACTERIUM TUBERCULOSIS GENETIC DIVERSITY AND DRUG RESISTANCE CONFERRING MUTATIONS
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationFrances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS
The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationGenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis
Eur Respir J 2008; 32: 1165 1174 DOI: 10.1183/09031936.00061808 CopyrightßERS Journals Ltd 2008 GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis D.I. Ling*,
More informationMaha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School. I have no financial or other potential conflicts of interest to disclose
Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School I have no financial or other potential conflicts of interest to disclose Update on the epidemiology of TB drug resistance Success
More informationMycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2009, p. 3501 3506 Vol. 47, No. 11 0095-1137/09/$12.00 doi:10.1128/jcm.01209-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Mycobacterium
More informationNorgen s HIV proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad icycler
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com HIV Proviral DNA PCR Kit Product # 33840 Product Insert Background Information
More informationCytomegalovirus (CMV) End-Point PCR Kit Product# EP36300
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Cytomegalovirus (CMV) End-Point PCR Kit Product# EP36300 Product
More informationAcknowledgements. Transparency Declaration. Pyrazinamide resistance in multidrugresistant Mycobacterium tuberculosis isolates in Japan.
1164 Clinical Microbiology and Infection, Volume 16 Number 8, August 2010 CMI Acknowledgements We thank the members of the TB Task Force of Greater Lisbon and its Fast and Faster Track TB Programmes for
More informationDRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION
JOURNAL OF PREVENTIVE MEDICINE 2008; 16(3-4): 3-9 Inviting Editorial DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION Harshad Thakur Centre for Health Policy, Planning and Management,
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationTuberculosis Disparity Between US-born African-Americans and Caucasians in Houston:
Tuberculosis Disparity Between US-born African-Americans and Caucasians in Houston: A population-based study Jose A. Serpa 1, M.D.; Larry D. Teeter 2, Ph.D., James M. Musser 2, M.D., Ph.D. and Edward A.
More information- UPDATE - Implementation and roll-out of Xpert MTB/RIF October 2011
- UPDATE - Implementation and roll-out of Xpert MTB/RIF October 2011 This document provides an update on the global roll-out of Xpert MTB/RIF, the WHO-endorsed test for the rapid and simultaneous detection
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More information